Jumpcode Genomics, Inc. – Trademark Portfolio
Entity Type: 03
Jumpcode Genomics, Inc. owns a portfolio of 9 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), including well-known marks such as DEPLETEX, JUMPCODE, and CRISPRCLEAN. Of these, 5 are registered and 2 are pending. The portfolio spans 3 Nice Classification classes, led by Class 1 (Chemicals) and Class 42 (Computer & Scientific). Headquartered in San Diego, CA.
10055 Barnes Canyon Rd, Suite 400
San Diego, CA 92121
Showing of trademarks Trademarks
Trademark Classifications
Jumpcode Genomics, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Jumpcode Genomics, Inc. have?
Jumpcode Genomics, Inc. has 9 U.S. trademarks filed with the USPTO. Of these, 5 registered, 2 pending, 2 abandoned.
What trademark classes does Jumpcode Genomics, Inc. file in?
Jumpcode Genomics, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are Jumpcode Genomics, Inc.'s most well-known trademarks?
Jumpcode Genomics, Inc.'s registered trademark portfolio includes well-known marks such as DEPLETEX, JUMPCODE, and CRISPRCLEAN. These are among 5 currently registered trademarks in the portfolio.
What is Jumpcode Genomics, Inc.'s trademark registration success rate?
Jumpcode Genomics, Inc. has a 71% trademark registration rate, with 5 out of 7 resolved applications resulting in successful registration. Currently, 2 applications are pending review.